Mechanism-based Therapeutic Discovery in Breast Cancer

Ruth A. Keri, Ph.D.
Arline H. and Curtis F. Garvin, MD., and
Constance C. Frackleton Professor in Cancer Research
Professor and Vice Chair, Department of Pharmacology
Associate Director for Basic Research, Case Comprehensive Cancer Center
School of Medicine
Case Western Reserve University

At the conclusion of this activity, the participant will be able to:

1. Attendees will be able to discriminate between subtypes of breast cancer and the importance of these subtypes in treating disease.
2. Attendees will be able to explain the limitations of mTOR inhibition for cancer therapy and approaches used to overcome those limitations.
3. Attendees will be able to describe the mechanisms of action of the epigenetic BET inhibitors in triple negative breast cancer.

Accreditation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships: The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose: Nothing to disclose